Luzhu Bio Files for Hong Kong IPO After RMB 4.42 Billion Valuation
Beijing Luzhu Biotechnology Co., Ltd, a leading developer of human vaccines and therapeutic biologics, has...
Youwe Bio’s Series B Financing to Advance Microneedle Technology Commercialization
China-based Youwe (Zhuhai) Biotechnology Co., Ltd, a developer of soluble microneedle transdermal drug delivery technology,...
NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals
The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL)...
Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...
Jixing Pharmaceuticals’ Aficamten Receives CDE Approval for Phase III HCM Study
China-based Ji Xing Pharmaceuticals announced receiving approval from the Center for Drug Evaluation (CDE) to...
BDgene Advances CRISPR-Based BD111 for Herpes Keratitis with IND Filing
Shanghai BDgene Technology Co., Ltd has completed efficacy and preliminary safety studies for BD111, its...
MicroPort NeuroTech Lists in Hong Kong with $43.3 Million IPO
MicroPort NeuroTech Limited has successfully completed its initial public offering (IPO) on the Hong Kong...
Bayer’s Kerendia Approved by China’s NMPA for Diabetic Kidney Disease
The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia...
Hengrui Medicine’s SHR3680 Approved for High Burden Metastatic Prostate Cancer
China’s Hengrui Medicine Co., Ltd. (SHA: 600276) announced that its Category 1 drug SHR3680 has...
Legend Biotech Collaborates with Trinity College Dublin on CAR-T Therapies for Solid Tumors
China-based Legend Biotech Corporation (NASDAQ: LEGN) has formed a partnership with Trinity College Dublin and...
AnchorDx and West China Hospital Collaborate on Lung Cancer Early Diagnosis
Guangzhou-based AnchorDx and West China Hospital of Sichuan University have entered into a transfer agreement...
Akeso Biopharma’s Cadonilimab Approved for Cervical Cancer Treatment
China-based biotech company Akeso Biopharma (HKG: 9926) announced that its self-discovered bispecific antibody (BsAb) cadonilimab...
Humanwell Healthcare Wins NMPA Approval for RFUS-144 in Pain Management
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced receiving approval from the National Medical...
LaNova Medicines Secures Series B Funding to Advance Oncology Pipeline
China-based LaNova Medicines has successfully closed a Series B financing round, raising an undisclosed sum...
GenFleet Collaborates with BioLineRx to Develop Motixafortide for Pancreatic Cancer in China
China-based GenFleet Therapeutics has entered into a collaboration with Israel’s BioLineRx Ltd (NASDAQ: BLRX) to...
Henlius and Palleon Partner on HER2-Targeted Antibody-Sialidase Fusion Protein
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with US-based Palleon Pharmaceuticals...
Lundbeck Initiates TALISMAN Study on Multiple System Atrophy in China and EU
Danish-based Lundbeck (OTCMKTS: HLUBF) has announced plans to initiate a global investigational study on multiple...
OCON Healthcare Partners with Bio Genuine for China Marketing Rights and Women’s Health Product Development
Israel-based OCON Healthcare, a specialist in uterine drug delivery, has entered into a license agreement...
Expeclinlab Raises RMB 185 Million to Boost Clinical Mass Spectrometry Business
Focused Photonics Inc’s (SHE: 300203) subsidiary Expeclinlab has secured RMB 185 million (USD 27.7 million)...
Beijing Luzhu Biotechnology Secures Series C Funding for Meningococcal Vaccine Development
China-based Beijing Luzhu Biotechnology Co., Ltd has reportedly secured an undisclosed amount in a Series...